Klaus-Michael Debatin

from Wikipedia, the free encyclopedia

Klaus-Michael Debatin (born December 6, 1952 in Karlsruhe ) is a German doctor . He is the Medical Director of the University Clinic for Child and Adolescent Medicine in Ulm . He became known for his achievements in cancer research , especially in the field of apoptosis .

Career

Debatin studied medicine from 1971 to 1978 at the Universities of Ulm, Freiburg and Heidelberg and received his doctorate in 1979 from the University of Heidelberg .

This was followed by a scientific activity at the University of Heidelberg and at the Max Planck Institute for Immunobiology in Freiburg. In 1983 he moved to the University Children's Hospital in Heidelberg, where he completed his training as a specialist in paediatrics in 1989 and his habilitation in 1990. During this time he was a visiting scientist at the German Cancer Research Center in Heidelberg and completed stays abroad at the Dana-Farber Cancer Institute , Boston, at the Memorial Sloan-Kettering Cancer Center , New York, as well as at the Mario Negri Institute and the University Children's Clinic in Milan. As a Heisenberg fellow of the DFG, he carried out research from 1991 to 1994 at the National Cancer Institute in the USA, at the German Cancer Research Center, Heidelberg, and at the Hôpital Necker, Paris. He then took over the management of the hematology / oncology section of the Heidelberg University Children's Hospital (until 1997) and the “Molecular Oncology” department at the German Cancer Research Center (until 2002).

In 1996 he was appointed to the chair of paediatrics at Ulm University . He has been director of the University Clinic for Pediatric and Adolescent Medicine in Ulm since 1997 and Vice President of Ulm University since 2015 (previously from 2010 to 2014). From 2004 to 2010 he was also the dean of the Medical Faculty in Ulm, and from 2013 to 2015 Chief Medical Director of the Ulm University Hospital .

research

Debatin's research focus is on the analysis of programmed cell death (apoptosis). Its aim is to make knowledge about apoptosis signaling pathways useful for diagnosis and treatment of cancer.

In 1989, Debatin was one of the key figures in the characterization of the death receptor CD95 and for the first time demonstrated the triggering of apoptosis by activating a physiological signal cascade in leukemia . Apoptosis signaling pathways have been recognized as the principal mechanism of the action of cancer drugs. This created the basis for the further development of cancer therapy: Researchers were now able to examine the molecular background of the failure of cancer therapies and develop targeted countermeasures.

His research laboratory is still concerned with the question of sensitivity and resistance of leukemia and cancer cells for tumor therapy. In this context, the laboratory has developed preclinical models for acute leukemia and identified signaling pathways as prognostic factors for leukemia in childhood that can be influenced by inhibitors . In cell death research, his laboratory has shown ways in which tumor cells can be sensitized to induction of apoptosis. Furthermore, so-called metronomic combination therapies have been developed which combine modern cancer therapeutics with pharmacological inhibitors of survival signals in order to be able to reduce side effects without sacrificing the therapeutic effect.

Awards and memberships (selection)

Committees (selection)

Publications (selection)

  • V. Münch, L. Trentin, J. Herzig, S. Demir, F. Seyfried, JM Kraus, HA Kestler, R. Köhler, TFE Barth, G. Te Kronnie, KM Debatin, LH Meyer. Central nervous system involvement in acute lymphoblastic leukemia is mediated by vascular endothelial growth factor. In: Blood . 130 (5), Aug 3, 2017, pp. 643-654. doi: 10.1182 / blood-2017-03-769315
  • M. Wabitsch, JB Funcke, B. Lennerz, U. Kuhnle-Krahl, G. Lahr, KM Debatin, P. Vatter, P. Gierschik, P. Moepps, P. Fischer-Posovszky: Biologically inactive leptin and early-onset extreme obesity. In: N Engl J Med . 372 (1), Jan 1, 2015, pp. 48-54. doi: 10.1056 / NEJMoa1406653
  • N. Hartmann, JJ Messmann, F. Leithäuser, M. Weiswange, M. Kluge, H. Fricke, KM Debatin, G. Strauss: Recombinant CD95-Fc (APG101) prevents graft-versus-host disease in mice without disabling antitumor cytotoxicity and T-cell functions. In: Blood . 121 (3), Jan 17, 2013, pp. 556-565. doi: 10.1182 / blood-2012-04-423392
  • LH Meyer, SM Eckhoff, M. Queudeville, JM Kraus, M. Giordan, J. Stursberg, A. Zangrando, E. Vendramini, A. Möricke, M. Zimmermann, A. Schrauder, G. Lahr, K. Holzmann, M Schrappe, G. Basso, K. Stahnke, HA Kestler, G. Te Kronnie, KM Debatin: Early relapse in ALL is identified by time to leukemia in NOD / SCID mice and is characterized by a gene signature involving survival pathways. In: Cancer Cell . 19 (2), Feb 15, 2011, pp. 206-217. doi: 10.1016 / j.ccr.2010.11.014
  • LH Meyer, M. Queudeville, SM Eckhoff, U. Creutzig, D. Reinhardt, L. Karawajew, WD Ludwig, K. Stahnke, KM Debatin: Intact apoptosis signaling in myeloid leukemia cells determines treatment outcome in childhood AML. In: Blood. 111 (5), Mar 1, 2008, pp. 2899-2903. doi: 10.1182 / blood-2007-08-109058
  • KM Debatin: Chronic lymphocytic leukemia: keeping cell death at bay. In: Cell . 129 (5), Jun 1, 2007, pp. 853-855. doi: 10.1016 / j.cell.2007.05.023
  • KM Debatin, S. Fulda (Ed.): Apoptosis and Cancer Therapy: From Cutting-edge Science to Novel Therapeutic Concepts. Wiley-VCH, Weinheim 2006. doi: 10.1002 / 9783527619665
  • LH Meyer, L. Karawajew, M. Schrappe, WD Ludwig, KM Debatin, K. Stahnke: Cytochrome c-related caspase-3 activation determines treatment response and relapse in childhood precursor B-cell ALL. In: Blood. 107 (11), Jun 1, 2006, pp. 4524-4531. doi: 10.1182 / blood-2005-08-3305 .
  • S. Fulda, W. Wick, M. Weller, KM Debatin: Smac agonists sensitize for Apo2L / TRAIL- or anticancer drug-induced apoptosis and induce regression of malignant glioma in vivo. In: Nat Med . 8 (8), Aug 2002, pp. 808-815. doi: 10.1038 / nm735 .
  • K. Stahnke, S. Fulda, C. Friesen, G. Strauss, KM Debatin: Activation of apoptosis pathways in peripheral blood lymphocytes by in vivo chemotherapy. In: Blood. 98 (10), Nov 15, 2001, pp. 3066-3073. doi: 10.1182 / blood.V98.10.3066 .
  • I. Jeremias, C. Kupatt, B. Baumann, I. Herr, T. Wirth, KM Debatin: Inhibition of nuclear factor kappaB activation attenuates apoptosis resistance in lymphoid cells. In: Blood. 91 (12), Jun 15, 1998, pp. 4624-4631. PMID 9616159 .
  • KM Debatin: Cytotoxic drugs, programmed cell death, and the immune system: defining new roles in an old play. In: J Natl Cancer Inst . 89 (11), Jun 4, 1997, pp. 750-751. doi: 10.1093 / jnci / 89.11.750 .
  • CB Bäumler, T. Böhler, I. Herr, A. Benner, PH Krammer, KM Debatin: Activation of the CD95 (APO-1 / Fas) system in T cells from human immunodeficiency virus type-1-infected children. In: Blood. 88 (5), Sep 1, 1996, pp. 1741-1746. PMID 8781430 .
  • C. Friesen, I. Herr, PH Krammer, KM Debatin: Involvement of the CD95 (APO-1 / FAS) receptor / ligand system in drug-induced apoptosis in leukemia cells. In: Nat Med. 2 (5), May 1996, pp. 574-577. PMID 8616718 .
  • F. Rieux-Laucat, F. Le Deist, C. Hivroz, IA Roberts, KM Debatin, A. Fischer, JP de Villartay: Mutations in Fas associated with human lymphoproliferative syndrome and autoimmunity. In: Science . 268 (5215) Jun 2, 1995, pp. 1347-1349. PMID 7539157 .
  • J. Dhein, H. Walczak, C. Bäumler, KM Debatin, PH Krammer. Autocrine T-cell suicide mediated by APO-1 / (Fas / CD95). In: Nature . 373 (6513), Feb 2, 1995, pp. 438-41. PMID 7530335 .
  • KM Debatin, CK Goldmann, R. Bamford, TA Waldmann, PH Krammer. Monoclonal-antibody-mediated apoptosis in adult T-cell leukaemia. In: The Lancet . 335 (8688), Mar 3, 1990, pp. 497-500. PMID 1689786 .
  • BC Trauth, C. Klas, AM Peters, S. Matzku, P. Möller, W. Falk, KM Debatin, PH Krammer: Monoclonal antibody-mediated tumor regression by induction of apoptosis. In: Science. 245 (4915), Jul 21, 1989, pp. 301-305. PMID 2787530 .

Web links

Individual evidence

  1. ↑ Our clinic team - Clinic for Child and Adolescent Medicine. Ulm University Hospital, accessed on November 6, 2018 .
  2. ↑ a b c d Member entry by Klaus-Michael Debatin at the German Academy of Natural Scientists Leopoldina , accessed on November 6, 2018.
  3. ↑ a b Curriculum Vitae Professor Dr. Klaus-Michael Debatin. (PDF) Leopoldina - National Academy of Sciences, accessed on April 29, 2014 .
  4. ^ Presidium. Ulm University, November 5, 2018, accessed on November 6, 2018 .
  5. ^ Pediatric Research. Ulm University Hospital, accessed on November 13, 2018 .
  6. ↑ Bernhard C. Trauth, Christiane Klas et al: Monoclonal antibody-mediated tumor regression by induction of apoptosis . In: Science . tape 245 , no. 4915 , 1989, pp. 301-305 , PMID 2787530 .
  7. ↑ Klaus-Michael Debatin et al: Monoclonal-antibody-mediated apoptosis in adult T-cell leukaemia . In: The Lancet . tape 335 , no. 8688 , 1990, pp. 497-500 , PMID 1689786 .
  8. ↑ Peter H. Krammer, Klaus-Michael Debatin: When apoptosis fails . In: Current Biology . tape 2 , no. 7 , 1992, pp. 383-385 , PMID 15335933 .
  9. ↑ Lüder H. Meyer, Sarah M. Eckhoff et al .: Early relapse in ALL is identified by time to leukemia in NOD / SCID mice and is characterized by a gene signature involving survival pathways . In: Cancer Cell . tape 19 , no. 2 , 2011, p. 206-217 , doi : 10.1016 / j.ccr.2010.11.014 .
  10. ↑ Manon Queudeville, Felix Seyfried et al .: Rapid engraftment of human ALL in NOD / SCID mice involves deficient apoptosis signaling . In: Cell Death & Disease . tape 3 , 2012, p. e364 , doi : 10.1038 / cddis.2012.107 .
  11. ↑ Jiwu Wei, Joachim Wahl et al .: Targeted release of oncolytic measles virus by blood outgrowth endothelial cells in situ inhibits orthotopic gliomas . In: Gene Therapy . tape 14 , no. 22 , 2007, p. 1573-1586 , PMID 17898797 .
  12. ↑ Mike-Andrew Westhoff, Shaoxia Zhou et al .: Identification of a novel switch in the dominant forms of cell adhesion-mediated drug resistance in glioblastoma cells . In: Oncogene . tape 27 , no. 39 , 2008, p. 5169-5181 , PMID 18469856 .
  13. ↑ Stefanie Enzenmüller, Patrick Gonzalez et al .: Chloroquine overcomes resistance of lung carcinoma cells to the dual PI3K / mTOR inhibitor PI103 by lysosome-mediated apoptosis . In: Anticancer Drugs . tape 24 , no. 1 , 2013, p. 14-19 , PMID 23111416 .
  14. ↑ Claudia Friesen, Mareike Roscher et al: Cell death sensitization of leukemia cells by opioid receptor activation . In: Oncotarget . tape 4 , no. 5 , 2013, p. 677-690 , PMID 23633472 .
  15. ↑ Jochen Tuettenberg, Marcel Seiz et al .: Pharmacokinetics, pharmacodynamics, safety and tolerability of APG101, a CD95-Fc fusion protein, in healthy volunteers and two glioma patients . In: International Immunopharmacology . tape 13 , no. 1 , 2012, p. 93-100 , doi : 10.1016 / j.intimp.2012.03.004 .
  16. ↑ Daniela Opel, Ivonne Naumann and others: Targeting aberrant PI3K / Akt activation by PI103 restores sensitivity to TRAIL-induced apoptosis in neuroblastoma . In: Clinical Cancer Research . tape 17 , no. 10 , 2011, p. 3233-3247 , doi : 10.1158 / 1078-0432.CCR-10-2530 .
  17. ↑ Mike-Andrew Westhoff, Oliver Brühl et al: Killing me softly-future challenges in apoptosis research . In: International Journal of Molecular Sciences . tape 15 , no. 3 , 2014, p. 3746-3767 , doi : 10.3390 / ijms15033746 .
  18. ↑ Annual Report 2011. (PDF) German Cancer Aid, accessed on June 11, 2018 .
  19. ↑ Three Excellent European Research Projects share € 1m Descartes Prize for Research. European Commission, March 7, 2007, accessed April 29, 2014 .
  20. ^ The members of the HAW since its foundation in 1909 - D. Heidelberg Academy of Sciences, accessed on April 29, 2014 .
  21. ↑ German Cancer Prize. (PDF) DKG Cancer Society, archived from the original on August 11, 2014 ; accessed on March 2, 2016 .
  22. ^ DFG committees - Senate. German Research Foundation, April 23, 2014, accessed April 28, 2014 .
  23. ↑ Seven new members in the Senate of the DFG. German Research Foundation, July 5, 2017, accessed on October 11, 2018 .
  24. ^ The boards and committees of the German Cancer Aid. German Cancer Aid, archived from the original on March 11, 2014 ; Retrieved April 28, 2014 .
  25. ^ The boards and committees of the German Cancer Aid. German Cancer Aid, archived from the original on June 3, 2015 ; Retrieved July 24, 2015 .
  26. ↑ MFT Presidium - About us. Medical Faculty Day, archived from the original on October 11, 2011 ; Retrieved April 28, 2014 .
  27. ↑ MFT Presidium - About us. Medical Faculty Day, archived from the original on July 24, 2015 ; Retrieved July 24, 2015 .
personal data
SURNAME Debatin, Klaus-Michael
BRIEF DESCRIPTION German oncologist
DATE OF BIRTH December 6, 1952
PLACE OF BIRTH Karlsruhe